Bristol Myers Squibb Target of Unusually Large Options Trading (NYSE:BMY)

Bristol Myers Squibb Company (NYSE:BMY) was the target of some unusual options trading activity on Tuesday. Stock investors purchased 53,552 call options on the company. This represents an increase of approximately 135% compared to the typical volume of 22,749 call options.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb is continuing its collaboration with Arcus Biosciences on a kidney cancer trial, adding Arcus’s investigational drug casdatifan to Bristol Myers’ Phase 1/2 ROSETTA RCC-208 study. The update reinforces BMY’s pipeline activity in oncology, which could support long-term growth if the combination shows promise. Article Title
• Positive Sentiment: Several articles highlighted Bristol Myers Squibb as a value stock and a “trending” name, which can attract investor interest and reinforce the view that BMY may be attractive at its current valuation relative to peers. Article Title
• Positive Sentiment: Unusually heavy call-option activity suggests some traders are positioning for a rebound or a near-term move higher in Bristol Myers Squibb shares. Article Title
• Neutral Sentiment: Brisbane Myers Squibb was added to Russell 1000 Value Defensive and Defensive indexes while being removed from growth-oriented benchmarks. This mainly reflects a style reclassification rather than a direct business change, though it may influence fund flows and how investors view the stock. Article Title
• Negative Sentiment: Erste Group slightly lowered its FY2026 EPS estimate for BMY to $6.31 from $6.32, a small cut that nevertheless signals modestly softer expectations for earnings growth. Article Title
• Negative Sentiment: Concerns about proposed Medicare drug-price negotiation changes remain a headwind for Bristol Myers Squibb, since policy pressure on drug pricing could affect future revenue and margins. Article Title

Analyst Ratings Changes

A number of equities research analysts have weighed in on BMY shares. Cantor Fitzgerald boosted their target price on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, April 8th. Bank of America dropped their price target on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Guggenheim reaffirmed a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Eight equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Trading Down 2.0%

BMY opened at $56.46 on Thursday. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $62.89. The company has a fifty day moving average of $56.95 and a 200-day moving average of $57.44. The stock has a market cap of $115.30 billion, a PE ratio of 15.86, a price-to-earnings-growth ratio of 0.16 and a beta of 0.23. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the prior year, the firm posted $1.80 earnings per share. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts predict that Bristol Myers Squibb will post 6.32 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.5%. Bristol Myers Squibb’s dividend payout ratio is presently 70.79%.

Hedge Funds Weigh In On Bristol Myers Squibb

Several institutional investors have recently added to or reduced their stakes in BMY. Brighton Jones LLC increased its stake in Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC grew its stake in shares of Bristol Myers Squibb by 59.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 2,786 shares during the period. United Bank grew its stake in shares of Bristol Myers Squibb by 15.0% in the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after buying an additional 3,277 shares during the period. Marshall Wace LLP bought a new stake in Bristol Myers Squibb in the 2nd quarter valued at about $221,000. Finally, Nebula Research & Development LLC bought a new stake in Bristol Myers Squibb in the 2nd quarter valued at about $405,000. 76.41% of the stock is owned by institutional investors and hedge funds.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.